Business Wire

CÆLUM-CAPITAL

5.5.2022 11:02:12 CEST | Business Wire | Press release

Share
London-Based Cælum Capital Limited Invests in Pioneering Scotch Whisky Business – Compass Box

Cælum Capital Limited, a specialist investor focused on premium beverage businesses, announced the acquisition of a majority stake in Compass Box Delicious Whisky Limited, a London-based premium Scotch whisky brand. Compass Box is ranked 4th in the “Top Trending Brands” in Scotch whisky segment by Drinks International.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220505005290/en/

Cælum was set up by Manish Rungta, an ex-Diageo executive with a background in private equity. Cælum has brought in Maurice Doyle as the new CEO of Compass Box to partner with the Founder, John Glaser, in the continued development of the business. A spirits industry veteran, Maurice Doyle brings nearly 30 years of marketing, commercial, and executive leadership experience from within the global alcoholic beverages sector. “I am delighted to be joining Compass Box. It is a brand that I have long admired as a pioneer within Scotch whisky. I have a huge amount of respect for John and what he has achieved,” says Doyle.

Founded in London in 2000, Compass Box is a reflection of Glaser’s personal vision for what the future of whisky making should be. John Glaser was named by Whisky Advocate as one of the “Thirty Innovators Who Shaped Today’s Whisky” and one of the only Two alive today. “With Maurice joining me at the helm, we are excited to double-down on our determination to democratise the enjoyment of Scotch whisky, to continue releasing products that reveal the creative art behind blending,” says Glaser, who has described the Compass Box mission as, “fighting…what I call the ‘single malt hegemony.’”

Cælum investment will be used to strengthen the balance sheet of the Company, acquire inventory, and build production facilities. Cælum will help facilitate the ambition of Compass Box to provide more opportunities to explore, experiment and innovate, with curiosity and creativity as its guiding principles. Manish Rungta, the Managing Partner at Cælum said, “We are excited to partner with Compass Box and it is representative of the innovative and pioneering brands within the beverage category that we would like to invest behind.”

Metric Point Capital, acted as the exclusive financial advisor and placement agent to Cælum. “We are thankful for the support of the Metric Point team during a very complex process and a crowded North American fundraising market. Metric Point brought highly technical skillsets and a tailored solution for this unique proprietary deal and we ended up being oversubscribed in our fundraising,” said Manish Rungta.

Corporate Partner Tom Braiden led the team at Brown Rudnick, an international law firm, which acted as exclusive legal advisor to Cælum.

Cælum Capital Limited
Cælum Capital Limited is based in London and is a specialist investor focused on investing in premium beverage businesses based in North America and Europe with a focus on alcoholic beverages. Cælum was founded by Manish Rungta, who is the Managing Partner of the firm and has extensive investment experience in the beverage sector, both alcoholic and non-alcoholic. Ex-SABMiller executive Mark Eames has joined Cælum as an Operating Partner and has extensive strategic, operational, and financial planning experience within the beverage sector. Cælum targets opportunities in the beverage segment with investment amounts ranging from US$50 – 200 million. For more information, please visit www.caelumcap.co.uk .

Compass Box
Compass Box are Scotch whiskymakers. The word ‘whiskymaker’ is their word – it does not appear in a dictionary. For over 20 years they have been relentlessly focused on reinventing Scotch whisky, with every new blend designed to help make the world of whisky a more interesting place. Compass Box have won more awards for innovation than any other producer in Scotland because they are always experimenting. Always looking for sparks of creativity that will deliver something totally compelling, yet completely surprising. This vision motivates them as whiskymakers. Their blends are consistently rated equal to or better than the great single malts of Scotland by the most respected voices in the industry. For more information, please visit www.compassboxwhisky.com or @CompassBoxWhiskyCo on Instagram.

Metric Point Capital (Member FINRA and SIPC)
Metric Point Capital is a boutique private capital advisory firm specializing in raising institutional capital for alternative investment managers.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release

SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye